ArticleTrends in biochemical sciences2022
A 'NAC' for targeting proteins to the ER.
Article in Trends in biochemical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NAC and Zuotin/Hsp70 chaperone systems coexist at the ribosome tunnel exit in vivo.Nucleic acids research · 2024Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
The signal recognition particle (SRP) cotranslationally targets a large and diverse portion of the nascent proteome to the endoplasmic reticulum (ER). A recent study by Jomaa et al. reveals an unexpected function for the ribosome-bound nascent chain-associated complex (NAC) in sensing ER-targeting signals and recruiting SRP to the appropriate ribosomes for high-fidelity targeting.
Indexed as
Identifiers
35501234What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.